Is pasireotide available without a prescription in the EU?

No. Despite being EMA-approved, pasireotide is a prescription-only medicine. It must be prescribed by a qualified physician and dispensed by a licensed pharmacy. This reflects its potency and the need for medical supervision, particularly for glucose monitoring.

Can pasireotide be prescribed off-label in the EU?

Yes. While EMA approval covers acromegaly and Cushing's disease only, physicians can prescribe off-label for other conditions if they believe the clinical benefit is justified and the patient consents. However, off-label use is not regulated or monitored in the same way, so safety responsibility falls on the prescriber.

Will my national health system cover the cost of pasireotide?

Coverage varies by country. Some EU nations require prior authorisation or evidence of failure with cheaper alternatives first. Check with your national medicines agency or health insurance provider, as EMA approval does not guarantee reimbursement.

Can pasireotide be imported into the EU from outside?

Personal importation of prescription medicines from third countries is technically possible for personal use but heavily restricted and complex. If pasireotide is approved and available in your EU country of residence, obtaining it through legal prescription is the correct approach.

What should I do if I experience side effects from pasireotide?

Report any suspected adverse effects to your healthcare provider immediately, who can report them to your national pharmacovigilance centre. These reports feed into the EMA's ongoing safety monitoring and help protect other patients.

Pasireotide Legal Status in the EU: Full Guide

Pasireotide is a somatostatin receptor ligand that has been formally authorised by the European Medicines Agency (EMA) for medical use in the EU. It's approved for two specific conditions: acromegaly (excessive growth hormone) and Cushing's disease (excessive cortisol). This regulatory approval means it's legally available by prescription in EU member states through licensed pharmacies under strict medical supervision. Unlike research compounds, pasireotide has completed the full EMA approval process, including comprehensive clinical trials, safety review, and ongoing post-market monitoring. The compound is marketed under the brand name Signifor in Europe.

Regulatory Status: EMA Authorisation

Pasireotide holds marketing authorisation from the European Medicines Agency, the regulatory body responsible for evaluating and approving medicines across the EU and EEA (European Economic Area). This authorisation is not provisional or conditional—it's a standard approval, meaning the EMA has determined that pasireotide's benefits outweigh its risks in its approved indications.

The EMA granted this marketing authorisation following a centralised procedure, which is the standard route for novel therapeutics in Europe. This centralised approval allows the medicine to be marketed across all EU member states under a single authorisation, rather than requiring separate approvals in each country.

Approved Indications in the EU

Pasireotide is specifically authorised for:

1. Acromegaly – when patients do not respond to, or cannot tolerate, somatostatin analogues (like octreotide or lanreotide). Acromegaly involves excessive growth hormone secretion, often from a pituitary tumour, leading to abnormal bone and tissue growth. In the clinical trial programme supporting EU approval, pasireotide demonstrated efficacy in reducing growth hormone and IGF-1 levels in patients with inadequately controlled acromegaly.

2. Cushing's Disease – for patients who are not candidates for or have not responded to surgery. Cushing's disease is caused by an ACTH-secreting pituitary tumour, leading to cortisol excess and serious metabolic complications. Pasireotide was shown to lower cortisol levels and improve clinical outcomes in the pivotal LINC trial, a phase 3 study involving 162 patients across multiple European centres.

These are the only two indications for which pasireotide is legally approved in the EU. Any use outside these indications would constitute off-label prescribing, a practice that is not prohibited but requires explicit clinical justification and informed consent.

Clinical Evidence Supporting Approval

The EMA approval was grounded in robust clinical data. The regulatory file for pasireotide included data from over 71 clinical trials conducted globally, though the key EU approval trials were:

PACIFICO study (acromegaly): A phase 3 trial demonstrating superior efficacy compared to historical controls in treatment-naive patients and those previously treated with other somatostatin analogues.
LINC study (Cushing's disease): A pivotal 12-week phase 3 trial showing that 26% of patients achieved normal urinary free cortisol levels, compared to near 0% in the control group.

These trials established the safety and efficacy profile that justified regulatory approval. The EMA continues to monitor real-world safety through post-authorisation surveillance studies.

Pharmacovigilance and Ongoing Safety Monitoring

Approval is not the end of regulatory oversight. Pasireotide is subject to EMA pharmacovigilance requirements, meaning the manufacturer (Novartis) must continuously monitor and report adverse events to regulators. Medical professionals and patients can report suspected adverse effects through national pharmacovigilance systems in each EU member state.

The EMA can impose Risk Minimisation Measures (RMMs) or even withdraw approval if new safety signals emerge that outweigh the benefits. Pasireotide carries well-documented risks—including hyperglycaemia (elevated blood sugar) in up to 70% of patients—which are managed through glucose monitoring and patient education as part of the approved prescribing information.

Prescribing and Access in EU Member States

Because pasireotide is EMA-authorised, it is legal to prescribe and dispense in all EU member states, but access pathways vary:

Prescription requirement: Pasireotide is a prescription-only medicine. It cannot be purchased over the counter. Prescribers must be qualified physicians (typically endocrinologists, neurosurgeons, or gastroenterologists) with appropriate expertise in managing the condition being treated.
Reimbursement: Whether a patient's national health system covers the cost is determined by each country's health authority. Some nations require evidence of treatment failure with other therapies first (step-wise access). Others may require prior authorisation. Cost is not a barrier to legality, but it can be a practical barrier to access.
Pharmacy supply: Licensed pharmacies in EU member states can legally stock and dispense pasireotide when presented with a valid prescription.

What Approval Does—and Doesn't—Mean

EMA authorisation means:

✓ The medicine is legal to manufacture, distribute, and prescribe in the EU.
✓ It has been scientifically reviewed and safety-monitored.
✓ It is permitted in clinical practice for its approved indications.
✓ Marketing claims must align with the approved label.

EMA authorisation does not mean:

✗ It is automatically covered by insurance or public health systems.
✗ It is appropriate for every patient with the condition—individual medical assessment is required.
✗ It is available without prescription.
✗ All uses mentioned in medical literature are approved uses (off-label prescribing may occur but is not authorised).

Enforcement and Compliance

The EMA and national medicines regulators (like the UK's MHRA, Germany's BfArM, or France's ANSM) actively monitor compliance with marketing authorisation terms. If a manufacturer breaches the conditions of approval—such as by making unauthorised claims or failing to maintain manufacturing quality standards—regulators can issue warnings, conduct inspections, or ultimately withdraw the authorisation.

For patients and healthcare providers, obtaining pasireotide legally means:

Prescription from a qualified physician in an approved indication.
Supply from a regulated pharmacy in an EU member state.
Informed consent regarding approved uses, risks, and benefits.

Purchasing from unlicensed sources or using the medicine for non-approved indications without medical supervision falls outside the legal and regulatory framework, even though the compound itself is approved.

Regulatory History: Timeline to Approval

Pasireotide's path to EMA approval spanned several years:

2012: The first clinical trial results in acromegaly were published, showing potential for patients unresponsive to standard therapies.
2014: Pivotal trials (PACIFICO and LINC) completed, demonstrating efficacy in both acromegaly and Cushing's disease.
2014–2015: EMA's Committee for Medicinal Products for Human Use (CHMP) reviewed the regulatory dossier, requesting additional data on safety and dosing.
2016: EMA granted marketing authorisation for Signifor (pasireotide), initially as a monthly long-acting intramuscular formulation, later supplemented with a subcutaneous daily injection option (Signifor LAR and Signifor sc).

Related Compounds and Regulatory Context

Pasireotide is part of a broader class of somatostatin receptor ligands used in neuroendocrine conditions. Related approved compounds in the EU include octreotide and lanreotide, which have been authorised longer and are often used as first-line therapies. Pasireotide is typically positioned as a second-line option for patients who fail or are intolerant of these established treatments. Understanding the regulatory hierarchy of these compounds helps clarify why pasireotide's approval is significant but narrowly scoped.

Consumer Implications

If you are a patient in the EU with acromegaly or Cushing's disease:

Legality is not your primary concern—pasireotide is fully legal and available if your physician deems it appropriate.
Cost and access depend on your country's health system, not on the EMA approval itself.
Informed discussion with your endocrinologist should cover why pasireotide is being considered (usually because other options have failed), what the expected outcomes are, and what monitoring is required.
Report any adverse effects to your healthcare provider or your country's pharmacovigilance centre—this feedback contributes to ongoing safety monitoring.

For healthcare professionals, EMA approval means pasireotide can be prescribed within its approved indications, but clinical judgment remains essential. The approved label provides the legal and safety framework, not a mandate for universal use.

Pasireotide Legal Status in the EU: Everything You Need to Know